| Literature DB >> 35303273 |
Germán Berrecoso1,2,3, José Crecente-Campo4,5,6, María José Alonso7,8,9.
Abstract
Nanocapsules (NCs) are drug delivery nanosystems that contain an oily core, stabilized by a surfactant, and surrounded by a polymeric shell. The assembling of the components is based on physical and physicochemical forces, and, hence, usually, only a fraction of each component is finally part of the NCs' structure, while the remaining amount might be solubilized or forming micelles in the NCs' suspending medium. Usually, reports on the characterization of nanostructures simply indicate the association efficiency of the loaded drugs instead of their complete final composition. In this work, we have developed a liquid chromatography (LC) mass spectrometry (MS) methodology that allows the quantification of all the components of a series of NCs prepared by different techniques, namely DL-α-tocopherol; D-α-tocopherol polyethylene glycol 1000 succinate; benzethonium; lecithin; hexadecyltrimethylammonium; 1,2-dioleoyl-3-trimethylammoniumpropane; caprylic/capric triglycerides; macrogol 15-hydroxystearate; polysorbate 80; polysialic acid; hyaluronic acid; and polyethylene glycol polyglutamic acid. The LC-MS method was validated in terms of linearity (0.9383 < r2 < 0.9997), quantification limits, and recoveries of the isolated NCs' and waste fractions. The final composition of the isolated NCs was found to strongly depend on their composition and preparation technique. In our view, the rigorous quantification of the exact composition of nanosystems is essential for the progress of nanotechnology. This quantitative analysis will allow researchers to draw more accurate conclusions about the influence of the nanosystems' composition on their biological performance.Entities:
Keywords: Mass spectrometry; Nanocapsules; Polymeric nanoparticles
Mesh:
Substances:
Year: 2022 PMID: 35303273 PMCID: PMC9512864 DOI: 10.1007/s13346-022-01150-5
Source DB: PubMed Journal: Drug Deliv Transl Res ISSN: 2190-393X Impact factor: 5.671
Fig. 1Schematic representation of the different prototypes of NCs and composition of the non-isolated samples. SD, solvent displacement; SE, self-emulsifying; l-PEG, polyethylene glycol (PEG) present in a linear disposition in the main surfactant; b-PEG, branched-disposed PEG on the main surfactant; noPEG, no PEGylated components. Polymers: HA, hyaluronic acid; PSA, polysialic acid; PEG·PGA, polyethylene glycol polyglutamic acid. PEGylated surfactants: TPGS, d-α-tocopherol polyethylene glycol 1000 succinate; Kol. HS15, Kolliphor® HS15, Tween® 80. Non-PEGylated surfactants: BZT, benzethonium; CTAB, hexadecyltrimethylammonium; DOTAP, 1,2-dioleoyl-3-trimethylammoniumpropane, lecithin. Oils: C8/C10 TGs, caprylic and capric acid triglycerides, α-tocopherol. The disposition of the components on the NC was assumed based on their physicochemical properties, mainly hydrophobicity and charge
Fig. 2Detected associated (green) and non-associated (red) mass percentages out of the total added mass of each component of the tested NCs. TPGS, d-α-tocopherol polyethylene glycol 1000 succinate; TGs, triglycerides; CTAB, hexadecyltrimethylammonium; DOTAP, 1,2-dioleoyl-3-trimethylammonium-propane chloride; PEG·PGA, polyethylene glycol polyglutamic acid. Data were plotted as mean ± standard deviation (n = 3)
Mass and molar ratios of PEGylated surfactants, non-PEGylated surfactants, and polymer, referred to the oil quantity
| Formulation | Mass ratio (mg/g of oil) | Molar ratio (mmol/mol of oil) | ||||
|---|---|---|---|---|---|---|
| PEGylated surfactants | Non-PEGylated surfactants | Polymer | PEGylated surfactants | Non-PEGylated surfactants | Polymer | |
| SD- | 238 | 20 | 36 | 68.31 | 20.89 | 0.27 |
| SD-noPEG-HA | N/A | 73 | 45 | N/A | 86.64 | 0.40 |
| SD-noPEG-PSA | N/A | 58 | 34 | N/A | 84.94 | 0.40 |
| SE- | 265 | 2 | 2 | 105.62 | 2.26 | 0.02 |
| SD-noPEG-PEG·PGA | N/A | 35 | 53 | N/A | 22.45 | 3.64 |
SD-l-PEG-HA, lineal-polyethylene glycol-containing hyaluronic acid nanocapsules formulated by solvent displacement; SD-noPEG-HA, non-PEGylated hyaluronic acid nanocapsules formulated by solvent displacement; SD-noPEG-PSA, non-PEGylated polysialic acid nanocapsules formulated by solvent displacement; SE-b-PEG-HA, self-emulsifying branched-polyethylene glycol-containing hyaluronic acid nanocapsules; SD-noPEG-PEG·PGA, solvent displacement nanocapsules with non-PEGylated surfactants and a shell of polyethylene glycol polyglutamic acid; N/A, not applicable
NCs’ composition after isolation
| Formulation | Compound | Expected concentration (mg·mL−1) | Actual concentration (mg·mL−1) (mean ± StD) ( |
|---|---|---|---|
| SD- | 18.00 | 12.99 ± 0.84 | |
| 5.33 | 3.09 ± 0.32 | ||
| Hyaluronic acid | 2.66 | 0.47 ± 0.08 | |
| Benzethonium | 0.67 | 0.26 ± 0.03 | |
| SD-noPEG-HA | Medium-chain triglycerides* | 20.40 | 10.55 ± 0.77 |
| Hyaluronic acid | 3.33 | 0.47 ± 0.06 | |
| Phosphatidylcholines** | 5.00 | 0.42 ± 0.08 | |
| Hexadecyltrimethylammonium | 1.00 | 0.35 ± 0.08 | |
| SD-noPEG-PSA | Medium-chain triglycerides* | 20.40 | 13.20 ± 1.60 |
| Phosphatidylcholines** | 5.00 | 0.46 ± 0.07 | |
| Polysialic acid | 3.33 | 0.45 ± 0.04 | |
| Hexadecyltrimethylammonium | 1.00 | 0.31 ± 0.04 | |
| SE- | Medium-chain triglycerides* | 59.00 | 55.01 ± 4.22 |
| Polysorbate 80 | 58.00 | 13.90 ± 5.26 | |
| Macrogol 15-hydroxystearate*** | 2.50 | 0.69 ± 0.09 | |
| Benzethonium | 0.20 | 0.10 ± 0.02 | |
| Hyaluronic acid | 0.25 | 0.11 ± 0.01 | |
| SD-noPEG-PEG·PGA | 18.00 | 17.07 ± 1.03 | |
| PEG·PGA | 2.67 | 0.91 ± 0.25 | |
| DOTAP | 0.67 | 0.59 ± 0.02 |
SD-l-PEG-HA, lineal-polyethylene glycol-containing hyaluronic acid nanocapsules formulated by solvent displacement; SD-noPEG-HA, non-PEGylated hyaluronic acid nanocapsules formulated by solvent displacement; SD-noPEG-PSA, non-PEGylated polysialic acid nanocapsules formulated by solvent displacement; SE-b-PEG-HA, self-emulsifying branched-polyethylene glycol-containing hyaluronic acid nanocapsules; StD, standard deviation. Solvent displacement nanocapsules with non-PEGylated surfactants and a shell of polyethylene glycol polyglutamic acid
*For quantification of the medium-chain triglycerides, a contribution of 25% of each quantified molecule was assumed; **Phosphatidylcholine concentration was corrected by its purity in the used batch of Epikuron™ 145 V (51.7%); ***Macrogol 15-hydroxystearate concentration was corrected by its purity in Kolliphor® HS15 (70%)